RESUMO
Background: Premenopause and menopause are nowadays a matter of public health due to the increasing life expectancy for women. Medical issues related to the period of premenopause and menopause are important, since they can alter the quality of women's life. Objectives:The goal of this prospective study is to determine the effect of an original formula consisting of phytoestrogens extracted from soy germs (Glycyne hisipida) with 40% isoflavones, vitamin E and grapeseed extract (Vitis vinifera) with 95% proanthocyanidins in reducing menopausal symptoms. Materials and methods: The present study had a six-month monitoring period in 2011 and involved four investigating physicians from "Bega" Clinical Hospital of Obstetrics and Gynecology, Timisoara, Romania. Outcomes: After six months of therapy there was a percentually decrease in menopause symptoms (irritability, depression, anxiety, hot flashes, etc); the most dramatic changes in the symptomatology of these women were noticed among premenopausal subjects. Conclusion:The original formula consisting of phytoestrogen, vitamin E and grapeseed extract can be applied in premenopause and surgically-induced menopause, and it is beneficial by decreasing the intensity of the symptomatology.
RESUMO
Background: Non-alcoholic fatty liver disease (NAFLD) has increased exponentially in recent years in Western European countries, where the number of hepatitis of viral etiology has been declining, and it is thought to be the most common cause of chronic liver disease in the near future (1). Currently, NAFLD is both the second most common cause of hepatocellular carcinoma (HCC) and the second most common indication for liver transplantation (2-4). This problem is very serious, as cases of NAFLDs are increasingly in children, a population with a long life ahead, and in whom the disease has all the time to progress to cirrhosis and HCC (5, 6). Objectives: The goal of this prospective study is to determine the effect of an original formula consisting in silymarin, organic selenium and alpha lipoic acid, in reducing liver damage in patients with chronic liver disease. Material and methods: The study started in March 2018, initially with a group of patients from Bucharest, integrated in the study at St. Mary's Hospital. In October 2018 it was expanded at the national level to 1 718 patients, monitored by 145 investigating physicians from 134 centers, with an average of 11.8 patients per investigating physician. Outcomes: Taking each stage of fatty liver disease (FLD) at T0 moment (the beginning of the study), we observed that 25% of patients with grade I FLD had no sign of disease at the end of the study, 74% of those with grade II FLD recovered or improved their health, and 83% of patients with grade III FLD recovered or improved their health. There were 149 patients with no FLD detected at the end of the study (recovered). Conclusion: Based on triple antioxidant therapy, the original formula improved the evolution and prognosis of patients with chronic liver disease.
